These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 16638863

  • 1. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ.
    Clin Cancer Res; 2006 Apr 15; 12(8):2538-44. PubMed ID: 16638863
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.
    BMC Cancer; 2006 Dec 06; 6():277. PubMed ID: 17150102
    [Abstract] [Full Text] [Related]

  • 3. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES.
    J Clin Oncol; 2010 Feb 10; 28(5):744-52. PubMed ID: 20038723
    [Abstract] [Full Text] [Related]

  • 4. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
    Soh J, Toyooka S, Ichihara S, Fujiwara Y, Hotta K, Suehisa H, Kobayashi N, Ichimura K, Aoe K, Aoe M, Kiura K, Date H.
    Int J Cancer; 2007 Sep 01; 121(5):1162-7. PubMed ID: 17487844
    [Abstract] [Full Text] [Related]

  • 5. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B.
    J Clin Oncol; 2006 Nov 01; 24(31):5034-42. PubMed ID: 17075123
    [Abstract] [Full Text] [Related]

  • 6. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
    Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M.
    J Clin Oncol; 2007 Jun 01; 25(16):2248-55. PubMed ID: 17538169
    [Abstract] [Full Text] [Related]

  • 7. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK.
    J Clin Oncol; 2005 Apr 10; 23(11):2493-501. PubMed ID: 15710947
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M.
    J Natl Cancer Inst; 2005 May 04; 97(9):643-55. PubMed ID: 15870435
    [Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.
    J Thorac Oncol; 2008 Dec 04; 3(12):1446-53. PubMed ID: 19057271
    [Abstract] [Full Text] [Related]

  • 10. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A.
    Lung Cancer; 2010 Mar 04; 67(3):355-60. PubMed ID: 19473722
    [Abstract] [Full Text] [Related]

  • 11. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
    Toyooka S, Uchida A, Shigematsu H, Soh J, Ogino A, Takata M, Kiura K, Ouchida M, Kosaka T, Aoe M, Mitsudomi T, Date H.
    J Thorac Oncol; 2007 Apr 04; 2(4):321-4. PubMed ID: 17409805
    [Abstract] [Full Text] [Related]

  • 12. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF.
    Lung Cancer; 2008 Sep 04; 61(3):328-39. PubMed ID: 18304690
    [Abstract] [Full Text] [Related]

  • 13. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M, Toyooka S, Ichihara S, Ohashi K, Tsukuda K, Ichimura K, Tabata M, Kiura K, Aoe M, Sano Y, Date H, Shimizu N.
    Lung Cancer; 2006 Jul 04; 53(1):117-21. PubMed ID: 16730855
    [Abstract] [Full Text] [Related]

  • 14. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Hirsch FR.
    J Clin Oncol; 2005 Aug 01; 23(22):5007-18. PubMed ID: 16051952
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
    Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR.
    Clin Cancer Res; 2006 May 15; 12(10):3078-84. PubMed ID: 16707605
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T.
    J Clin Oncol; 2005 Oct 01; 23(28):6829-37. PubMed ID: 15998907
    [Abstract] [Full Text] [Related]

  • 17. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
    Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, Soh J, Asano H, Ichimura K, Aoe K, Aoe M, Kiura K, Shimizu K, Date H, Shimizu N.
    Int J Cancer; 2007 Mar 15; 120(6):1239-47. PubMed ID: 17192902
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni D, Daniele L, Barone C, Dongiovanni V, Fissore C, Sapino A, Macrì L, Bussolati G, Buffoni L, Gaspari F, Grillo R, Birocco N, Addeo A, Ciuffreda L, Schena M.
    Lung Cancer; 2008 Jul 15; 61(1):73-81. PubMed ID: 18243402
    [Abstract] [Full Text] [Related]

  • 19. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
    Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J.
    J Thorac Oncol; 2006 Jan 15; 1(1):52-60. PubMed ID: 17409827
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
    Endo K, Sasaki H, Yano M, Kobayashi Y, Yukiue H, Haneda H, Suzuki E, Kawano O, Fujii Y.
    Oncol Rep; 2006 Sep 15; 16(3):533-41. PubMed ID: 16865253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.